Regenerative medicine terms like “stem cells,” “tissues,” and “biological products” are specific regulatory categories, not proof that a treatment works. A stem cell is a cell that can copy itself and turn into other cell types. A tissue-based product is material taken from human cells or tissue and processed for use in another person.
The U.S. Food and Drug Administration (FDA) groups many of these under one regulatory label: human cells, tissues, and cellular and tissue-based products, or HCT/Ps. That label covers things like fat, bone, umbilical cord blood, amniotic fluid, and Wharton’s jelly (a substance found inside umbilical cords). Knowing what these terms mean does not tell you whether a specific product is safe or effective — that depends on evidence, not vocabulary. For a broader framework on weighing that evidence, see our Start Here guide.
What’s the Strongest Evidence Behind a Regenerative Medicine Claim?
Not every product using scientific-sounding language has been tested the same way. The strength of the evidence behind a term falls on one of three rungs, from weakest to strongest — and knowing which rung you’re standing on is the single most useful question you can ask.
Rung 1: The Word Alone
A provider or product description uses a term like “stem cell,” “regenerative,” “biologic,” or “cellular therapy.” On its own, a label like this says nothing about safety or effectiveness. According to the FDA, using scientific terminology is not evidence that a product works or has been proven safe.
Rung 2: A Description of the Source Material
You’re told where the cells or tissue came from — for example, your own fat tissue, umbilical cord blood, or amniotic fluid. This tells you the origin of the material. It does not tell you whether the specific product made from that material has been tested in people for the condition being treated.
Rung 3: FDA Approval for a Specific Use
The FDA has formally approved the product for a named condition. This is the strongest rung. As of the FDA’s current consumer guidance, the only stem cell products with this level of approval are blood-forming stem cells (also called hematopoietic progenitor cells) derived from umbilical cord blood, and only for disorders affecting the body’s blood-forming system. Most other regenerative medicine products marketed to consumers — including many stem cell, exosome, and stromal vascular fraction (fat-derived cell) products — do not have this approval for the uses they’re being sold for. Our How We Research page explains how we verify claims like this against primary sources rather than marketing language.
What Do We Actually Know About Regenerative Medicine Cells and Tissues?
This section separates what’s established from what isn’t, based on the FDA’s consumer guidance on regenerative medicine therapies and the National Institutes of Health’s stem cell basics resource.
What Is Established
- Stem cells have two defining properties: they can make copies of themselves, and they can develop into more specialized cell types.
- Adult (also called somatic) stem cells live in specific tissues and organs and generally form the specialized cells of that same tissue or organ.
- The only FDA-approved stem cell products for consumers are certain cord-blood-derived blood-forming stem cells, approved specifically for diseases affecting blood formation.
- The FDA has documented real harm from unapproved regenerative medicine products, including tumor formation, blindness, infections, and unintended tissue growth.
What Remains Unknown or Unproven for Most Marketed Products
- Whether a specific unapproved stem cell, exosome, or stromal vascular fraction product is safe for the condition it’s being marketed for.
- Whether that product is effective for that condition.
- How a given clinic’s processing method affects the final product’s safety, since processing varies between providers.
- Long-term outcomes for most cell-based procedures marketed directly to consumers outside of approved products or registered clinical trials.
If a claim falls into the “unknown or unproven” list, that’s not automatically a reason to rule it out — but it is a reason to ask more questions, and to treat “unproven” as a factual description, not an opinion.
Regenerative Medicine Terms Glossary
These definitions summarize language used in FDA and NIH consumer and public resources. They’re meant to help you follow a conversation with a licensed provider, not replace one.
| Term | What It Means | FDA-Approved for Marketed Uses? |
|---|---|---|
| Stem cell | A cell that can renew itself through cell division and develop into more specialized cell types. | Only one category — see cord blood row below. |
| Pluripotent stem cell | A stem cell able to develop into nearly any cell type in the body, including embryonic stem cells and induced pluripotent stem cells (reprogrammed adult cells). | Not approved for consumer marketed products. |
| Adult (somatic) stem cell | A stem cell found in a specific tissue or organ that mainly develops into the specialized cells of that same tissue or organ. | Not approved outside the cord-blood category below. |
| HCT/P | The FDA’s regulatory category for products made from human cells or tissue intended for transplantation into another person. | Depends on the specific product — not a blanket approval. |
| Stromal vascular fraction (SVF) | A mixture of cell types isolated from processed fat tissue, sometimes marketed as a source of “stem cells.” | Not approved for the conditions it’s commonly marketed for. |
| Exosomes | Tiny particles released by cells that carry molecules between cells. | Not approved for the conditions they’re commonly sold to treat. |
| Umbilical cord blood stem cells | Blood collected from the umbilical cord after birth, which can contain blood-forming stem cells. | Yes — the one FDA-approved category, for blood-formation disorders only. |
| Wharton’s jelly | A gel-like substance inside the umbilical cord, sometimes used as source material in unapproved regenerative products. | Not approved for marketed regenerative uses. |
| Amniotic fluid product | A product derived from the fluid surrounding a fetus during pregnancy. | Not approved for marketed regenerative uses. |
| Ortho-biologics | A marketing term for biologically derived products used in orthopedic (bone, joint, or tendon) procedures. | Describes intended use, not an approval status. |
What Should You Do Before a Regenerative Medicine Consultation?
If a provider tells you a product is FDA-approved, ask them to name the specific approval — cord-blood-derived blood-forming stem cells for blood-formation disorders is currently the only one that exists. If they can’t name a specific approval, treat the product as unapproved and unproven for your condition until shown otherwise. Use this checklist before you go in:
- Ask directly: “Is this specific product FDA-approved for my condition, or is it being offered without that approval?”
- Ask what source material is used (your own tissue, donor tissue, cord blood, etc.) and how it’s processed.
- Ask whether the treatment is part of a registered clinical trial, and if so, request the trial registration information.
- Write down every term used in the marketing material or consultation, and check it against the glossary above before your next conversation with the provider.
- If you’re told a product is “natural” or uses your “own cells,” ask whether that changes its approval status — according to the FDA, it generally does not.
- Report suspected illegal marketing of unapproved products to the FDA at ocod@fda.hhs.gov, and report any adverse reaction through the FDA’s MedWatch program.
When to Seek Care Right Away
If you experience signs of a serious reaction after any cell- or tissue-based procedure — sudden vision changes, difficulty breathing, high fever, signs of infection at an injection or infusion site, or any rapid, severe symptom — treat it as a medical emergency and contact local emergency services or go to the nearest emergency department immediately. Do not wait to see if the reaction resolves on its own.
Sources and Verification
This article is based on two authoritative sources: the FDA’s consumer guidance, Important Patient and Consumer Information About Regenerative Medicine Therapies, and the National Institutes of Health’s public stem cell resource, Stem Cell Basics. Every definition and claim above was checked against these sources before publication.
Medical Information Disclaimer
This article is for general educational purposes only and is not medical advice. It does not diagnose any condition, recommend any treatment, or replace consultation with a licensed healthcare provider. Regenerative Evidence Guide is an independent educational publication and is not affiliated with any clinic, academy, training program, or healthcare provider, including any prior operator of this domain. If you are experiencing a medical emergency, contact local emergency services immediately. See our full Medical Disclaimer for more information.
By Regenerative Evidence Guide Editorial Team. Last updated September 8, 2026.
Leave a Reply